Connect with us

Cannabis News

Are Psychedelics Cannabis 2.0? – The Benzinga Psychedelics Conference 2023

Published

on


 

benzinga psychedelics show

A funny thing happened on the way to Fort Lauderdale having Biblical flooding after the Benzinga Cannabis Capital Conference in Miami, with the airport closed for 48 hours, Cannabis.net got to stick around and cover the psychedelics show that follows the Benzinga cannabis show by one day.

 

The great part of this one-day show for us was that we got to sit through 8 hours of speakers and presentations since we were neophytes on the subject of “where psychedelics are legally, medically, etc”.  Instead of staying in the hallways and meeting people like a cannabis show, this show we decided to be students and sit through every presentation.  It was one of best “learning” days we ever had, this time around, we got to be the student and listen and learn. 

 

Let’s cover some the basics readers might have just like we had walking into the Psychedelics show.

 

Are psychedelics legal? – No, not at the Federal level, but Oregon and Colorado have legalized some psychedelics, and Quebec (Yes, we said Quebec!) has approved medical payments and use for some psychedelics. Vancouver, BC has decriminalized some psychedelics like mushrooms for personal use only. Well, aren’t some “psychedelics” legal then? Yes and no, but that leads us to the next question.

 

What defines a psychedelic? This is up for some debate within the industry as what are the “must haves” in order to officially be a psychedelic, but you may have heard of Ketamine and MDMA (ecstasy if you are old enough) as being in the news, and around you in your life.  These drugs are considered psychedelics by some and not by others in the industry.  Hallucinate or not, you will be hearing alot about the serotonin 2A receptor (5-HT2AR) as the industry advances, as that is the brain area psychedelics work with the most.

 

Ketamine is a drug being used to help people with depression and anxiety, and it is has been, and  is, completely legal at all levels, as in state and Federal. VA insurance programs approve payments and reimburses clinics for veterans who are prescribed ketamine sessions.  This was the first honeypot for the psychedelics industry, set up ketamine clinics next to VA hospitals.  Early investors and VC funds rushed into this model, but it appears to have cooled off by now with some early entrants bankrupt and closing clinics without notice.  MDMA is right behind ketamine for mainstream medical use with PTSD, so clinics that dispense both may have a future, especially by the right veterans’ hospitals.

 

Ketamine and MDMA are the closest thing to revenue generating positive cash-flow type deals going on in the psychedelic space right now.  Mushrooms, LSD, and psilocybin generate headlines and clicks but we are a long way from Federal legalization for these psychedelics.  Medical use could be on the horizon in the same way cannabis has rolled out with a dichotomy in state and Federal laws.  Some states may legalize medical use like cannabis, but changes to Federal law are a long time away.

 

Are psychedelics Weed 2.0?  No, yes, kind of. No, it is not a blueprint of cannabis legalization history and pathways, but as they say, “history may not repeat, but it does rhyme”.  There are some similarities between the two industries in trying to create revenue and get legitimacy.  For example, the cannabis industry loophole around “hemp now gets you high” with Delta-8 and Delta-9, is similar to “novel molecules” in the psychedelic industry.  A novel molecule is a brand-new compound or molecule you can create, patten, and get credit for down the road if a big discovery is made using your compound. So, LSD and psilocybin may be Schedule 1 illegal drugs, but this “novel compound that is one carbon atom different” is not illegal because it isn’t on the Controlled Substance List.  Change an atom or covalent bond, and boom, you have a loophole around the CSA list of banned drugs, but that new compound does 99% of what the outlawed one does. Sound familiar if you are in the cannabis industry?

 

How Does Anyone Make Money in Psychedelics Right Now? – Well, not many are making money, let alone have revenue yet.  Remember, this niche is 10 years behind the cannabis industry in emergence and public awareness. Almost every company is seeking investors and funding with the promise of future riches.  Similar issues exist from the cannabis industry with taxation as well, Ketamine is subject to the same 280E tax as cannabis as the Federal level.

 

But wait, how is anyone going to get rich in psychedelics to begin with?  The big homerun pitch is in the creation of as many novel molecules as a company can create and then get a patent on them as soon as possible.  There are thousands of patents being sent in by early state psychedelic companies as part of a “molecule land grab” if you will, being that if you own the patent on XYZ novel molecule, and it later helps to reverse dementia in seniors, guess what?  You just bought yourself an island.

 

Smart money is setting up their companies in this manner in order to someday, fingers crossed, be bought by Big Pharma.  An IPO or sale to Big Pharma is the homerun, so having IP (intellectual property) many at experts feel is the key to a big payday down the road.  If your company has a patent on 4,000 novel molecules that need research, the odds are better one of them turns out to be medically miraculous, as opposed to a company that may have 500 novel molecule patents. These novel molecules, many with no research being done on them, are like little lottery tickets for these very small psychedelics companies. Enveric Biosciences is publicly traded and is aggressive in following this model.  Psychedelics also has an ETF, from AdvisorShares, the symbol is PSIL, for psilocybin.

 

Remember, many, many early psychedelic companies don’t even have revenue and are long-shot bets.  If you want to move one step up the ladder to companies that at least have revenue, IP, and are publicly traded, check out the PSIL ETF, and click on their “holdings” tab.  That is a good place to start for publicly investable psychedelics as of now.

The other way to create cash is to follow the trends and jump on one fast, like the ketamine clinics by VA hospitals.  When we asked around how much do ketamine sessions cost, many told us it is sold as a 6-pack of therapy, each session lasts about 5 hours, and it costs between $2,500 and $3,000.  Wowza! We figured out once VA insurance agreed to pay, why clinics around VA hospitals become big!

 

Did you know the industry has its own Weemdaps called HealingMaps? It shows you locations for ketamine and MDMA clinics as well as gives the user the ability to overaly VA hospital information to see where there could be a busienss opportunity to set up a clinic.

 

What are the problems in industry? – No investment money and a long runaway that could veer in many directions and take years to get legal stature in the US.  Telemedicine has also hit them where it hurts as ketamine can now be approved and shipped to your house for self-dosing through most telemedicine doctors.

 

What are the 3 debates smart people are having in the industry?

 

  1. Hallucinate vs. Non-Hallucinate – Enveric is working on taking the “tripping balls” part of psychedelics due to medical purposes and not all patients may want or feel comfortable with that part of the new drugs. This has the industry torn on if it is a good idea or will have the same results as the “real deal” psilocybin. If you are in the cannabis industry and understand the “entourage effect argument vs. just individual cannabinoids” then you get the drift here.  Smart people on both sides are debating if the medical benefits and overall experience will be worth it or altered too much by taking out the “tripping part”.  On the other hand, if grandma can have dementia reversed and she and you don’t want her tripping balls, well…

  2. Clinics vs Retreats – Experts have different opinions on whether the industry should be built around clinics and regular treatments, or retreats and destination places to experience a psychedelics breakthrough.  Ayahuasca retreats or sessions at your local strip mall?  There is no right answer, and usually the best solution lies in between the two extremes.

  3. Telemedicine vs. traditional therapist relationships (aftercare debate)– Telemedicine, like in all areas, is eating into the margins of the traditional medical industry, same with psychedelics.  You can get ketamine doses with telehealth approval now and do them at home.  Coming out of ketamine session is a wild card and much like coming out of an LSD or shroom experience, counselors and people may be needed to help you.  Help can mean psychological help or psychical help, thinking of coming out of anesthesia after a colonoscopy, the nurse’s monitor, give you some time, some crackers and juice, etc.

 

 

Final Thoughts

The psychedelics industry in 10 to 15 years behind the cannabis boom and bust, so you have plenty of time to research companies and learn about the field.  Like all industries coming out of the darkness of society and into the light, there will be some educated and responsible people trying to lead the movement, as well as some more “interesting swashbucklers”. That is just what you get with an industry like weed, gambling, or shrooms becoming legal, some good intelligent science guys telling you why we can even talk about this stuff being legal, and some “get rich quick guys”.  While the morning session of the Benzinga conference rolled out a few characters that looked like they were villain-rejects from the 1972 Adam West Batman show, there were also intelligent, educated, well-spoken people who you could learn from and ask questions to and about the industry.

 

While psychedelics isn’t Marijuana 2.0, it does have some similarities around the novel molecule Delta-8 story, the entourage effect vs hallucination or not hallucinate, etc.   In the end this makes sense when you think about those drugs coming out of the 1960s.  The same guy who sold you weed back then probably sold you mushrooms and LSD, but the percentage of people smoking weed compared to trying psychedelics is probably 10 to 1.  Hence, the cannabis movement has a much broader base and support than the “let’s legalize LSD” crowd, at least for now.

 

Like any industry that has so many pre-revenue companies, be very careful who you give your money to in this space right now.  Super long shot dreamers may outnumber normal long shots by 10 to 1.  Many people will be sold on “we have the next medical breakthrough coming in novel molecule XCX” but without FDA testing and IP, many of those stories will run out of money well before their investors see any positive returns.  Just like betting on early state bio-pharma companies, for every single one bought by Pfizer, there are 100 that failed.

 

The industry has just barely begun, buyer beware and due dilligence will be key to many investment decisions right now.

 

BENZINGA CANNABIS CAPITAL CONFERENCE, READ ON…

BENZINGA CANNABIS CONFERENCE 2023

5 THINGS I LEARNED AT THE BENZINGA CANNABIS CONFERENCE, MIAMI!



Source link

Cannabis News

Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It

Published

on

By


trump on marijuana reform

In a recent interview, former New Jersey Governor Chris Christie made headlines by asserting that President-elect Donald Trump will pursue significant reforms in federal policies regarding marijuana and cryptocurrency. As the nation grapples with evolving attitudes toward cannabis and the burgeoning digital currency market, Christie’s predictions have ignited discussions about the potential implications of such changes on both industries. This article delves into Christie’s insights, the current state of marijuana and cryptocurrency regulations, and the broader implications of these anticipated reforms.

 

The Current Landscape of Marijuana Legislation

 

Federal vs. State Laws

Marijuana remains classified as a Schedule I substance under the Controlled Substances Act (CSA), which places it in the same category as heroin and LSD. This classification has created a complex legal landscape where states have moved to legalize cannabis for medical and recreational use, while federal law continues to impose strict prohibitions. As of now, over 30 states have legalized marijuana in some form, leading to a burgeoning industry that generates billions in revenue.

 

Challenges Faced by the Cannabis Industry

 

Despite its legality in many states, the cannabis industry faces significant hurdles due to federal restrictions. These challenges include:

  • Banking Access: Many banks are hesitant to work with cannabis businesses due to fear of federal repercussions, forcing these businesses to operate largely in cash.

  • Taxation Issues: The IRS enforces Section 280E of the tax code, which prohibits businesses engaged in illegal activities from deducting normal business expenses, leading to disproportionately high tax burdens for cannabis companies.

  • Interstate Commerce: The lack of federal legalization prevents cannabis businesses from operating across state lines, limiting their growth potential.

 

Chris Christie’s Perspective on Marijuana Reform

 

Christie, a former presidential candidate known for his tough stance on drugs during his tenure as governor, has evolved his views on marijuana over the years. In his recent statements, he emphasized that Trump is likely to pursue descheduling cannabis, which would remove it from the Schedule I classification. This move would not only provide clarity for businesses operating in legal markets but also open avenues for banking and investment.

 

Christie highlighted that descheduling would allow for a more regulated market where safety standards could be established, thus protecting consumers. He believes that this approach aligns with a growing consensus among Americans who support legalization and recognize the potential benefits of cannabis use for both medical and recreational purposes.

 

The Future of Cryptocurrency Regulation = The Rise of Cryptocurrencies

 

Cryptocurrencies have surged in popularity over the past decade, with Bitcoin leading the charge as the first decentralized digital currency. The market has expanded to include thousands of alternative coins (altcoins), each with unique features and use cases. As cryptocurrencies gain traction among investors and consumers alike, regulatory scrutiny has intensified.

 

Current Regulatory Challenges

 

The cryptocurrency market faces several regulatory challenges that hinder its growth and adoption:

 

  • Lack of Clarity: Regulatory frameworks vary significantly across states and countries, creating confusion for investors and businesses.

  • Fraud and Scams: The rapid growth of cryptocurrencies has led to an increase in fraudulent schemes targeting unsuspecting investors.

  • Consumer Protection: Without clear regulations, consumers are often left vulnerable to risks associated with volatile markets.

 

Christie’s Vision for Crypto Regulation

 

Christie believes that under Trump’s leadership, there will be an effort to find a “sweet spot” for cryptocurrency regulation balancing innovation with consumer protection. He argues that overly stringent regulations could stifle growth in this emerging sector while too little oversight could expose consumers to significant risks.

 

In his view, a balanced regulatory framework would include:

 

1. Clear Definitions: Establishing clear definitions for different types of cryptocurrencies and tokens to differentiate between securities and utility tokens.

2. Consumer Protections: Implementing measures to protect investors from fraud while promoting transparency within the market.

3. Encouraging Innovation: Creating an environment conducive to innovation by allowing startups to thrive without excessive regulatory burdens.

 

Christie’s insights reflect a growing recognition among policymakers that cryptocurrencies are here to stay and that appropriate regulations are necessary to foster growth while safeguarding consumers.

 

Implications of Proposed Reforms

 

Economic Impact

 

The potential reforms proposed by Christie could have far-reaching economic implications:

 

  • Job Creation: Legalizing marijuana at the federal level could lead to significant job creation within the cannabis industry—from cultivation and production to retail sales.

  • Investment Opportunities: Descheduling cannabis would open up investment opportunities for institutional investors who have been hesitant due to federal restrictions.

  • Boosting Local Economies: Legal cannabis markets have proven beneficial for local economies through increased tax revenues and job creation.

 

Similarly, clear regulations around cryptocurrencies could stimulate investment in blockchain technology and related industries, fostering innovation and economic growth.

 

Social Justice Considerations

 

Both marijuana legalization and sensible cryptocurrency regulations have social justice implications:

 

  • Addressing Past Injustices: Legalizing marijuana could help rectify past injustices related to drug enforcement policies that disproportionately affected marginalized communities.

  • Financial Inclusion: Cryptocurrencies offer opportunities for financial inclusion for those underserved by traditional banking systems, particularly in low-income communities.

 

Political Landscape

 

The political landscape surrounding these issues is complex. While there is bipartisan support for marijuana reform among certain lawmakers, challenges remain in overcoming entrenched opposition. Similarly, cryptocurrency regulation has garnered attention from both sides of the aisle but requires collaboration to establish effective frameworks.

 

Conclusion

 

Chris Christie’s predictions about President-elect Donald Trump’s approach to federal marijuana descheduling and cryptocurrency regulation suggest a potential shift in U.S. policy that could significantly reshape both industries. As public opinion evolves on these issues, lawmakers have an opportunity to enact meaningful reforms that promote economic growth while ensuring consumer protection. The anticipated changes could foster a more robust cannabis industry that contributes positively to the economy and addresses social justice concerns, while clear regulatory frameworks for cryptocurrencies could encourage innovation and protect consumers in the digital economy. Stakeholders in both sectors are closely watching these developments, eager to see how potential reforms might impact their futures. While the realization of Christie’s predictions remains uncertain, it’s clear that the conversation around marijuana and cryptocurrency regulation is ongoing and far from settled.

 

TRUMP 2.0 ON CANNABIS REFORM, READ ON…

TRUMP ON MARIJUANA REFORM

TRUMP 2.0 ON FEDERAL CANNABIS REFORM – WHAT DO WE KNOW?

 



Source link

Continue Reading

Cannabis News

Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em

Published

on

By


On Thursday, November 7th, Vince Sliwoski, Aaron Pelley and Fred Rocafort held a post election discussion “Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em”. Watch the replay!

Key Takeaways from the “Smoke ’em if You’ve Got ’em – 2024 Post Election Cannabis Wrap” Webinar:

  1. Panelists:
    • Vince Sliwoski: Oregon Business lawyer specializing in cannabis and commercial real estate.
    • Aaron Pelley: Experienced in cannabis law since Washington’s legalization in 2012.
    • Fred Rocafort: Trademark attorney working closely with the cannabis team.
  2. Election Results Overview:
    • Most 2024 cannabis ballot measures did not pass.
    • Florida, South Dakota, and North Dakota saw failures.
    • Nebraska became the 39th state to legalize cannabis for medical use when it passed two cannabis initiatives, Initiatives 437 and 438.
  3. Federal and State-Level Developments:
    • Medical use is currently legal in 38 states, and 24 states allow recreational use.
    • Republican support for marijuana legalization is growing.
  4. Federal Policy Implications:
    • Schedule III Rescheduling: The process to move cannabis to Schedule III is ongoing, which could significantly impact the industry.
    • Importance of Federal Appointments: The future of cannabis policy depends heavily on who is appointed to key positions in the administration.
  5. International and Domestic Trade:
    • Schedule III status could ease import/export restrictions on cannabis.
    • Unified control of House, Senate, and presidency might expedite legislative progress.
  6. Economic and Industry Impact:
    • Cannabis stocks experienced volatility post-election, reflecting investor uncertainty.
    • Federal legalization and banking reforms are crucial for industry stability and growth.
  7. Future Outlook:
    • The potential for federal rescheduling remains strong, with hearings scheduled for early 2025.
    • State-level initiatives and regulatory developments will continue to shape the industry.

Watch the replay!



Source link

Continue Reading

Cannabis News

I Had Just One Puff

Published

on

By


one puff of a joint a drug test

“How Long Does One Puff of Weed Stay in Your System?”… This topic can be difficult to answer since it is dependent on elements such as the size of the hit and what constitutes a “one hit.” If you take a large bong pull then cough, it might linger in your system for 5-7 days. A moderate dose from a joint can last 3-5 days, whereas a few hits from a vaporizer may last 1-3 days.

 

The length of time that marijuana stays in the body varies based on a number of factors, including metabolism, THC levels, frequency of use, and hydration.

 

Delta-9-tetrahydrocannabinol, or THC, is the primary psychoactive component of cannabis. THC and its metabolites, which remain in your body long after the effects have subsided, are detected by drug tests.

 

Since these metabolites are fat-soluble, they cling to bodily fat molecules. They could thus take a while to fully pass through your system, particularly if your body fat percentage is higher.

 

THC is absorbed by tissues and organs (including the brain, heart, and fat) and converted by the liver into chemicals such as 11-hydroxy-THC and carboxy-THC. Cannabis is eliminated in feces at a rate of around 65%, while urine accounts for 20%. The leftover amount might be kept within the body.

 

THC deposited in bodily tissues ultimately re-enters the circulation and is processed by the liver. For frequent users, THC accumulates in fatty tissues quicker than it can be removed, thus it may be detectable in drug tests for days or weeks following consumption.

 

The detection time varies according to the amount and frequency of cannabis usage. Higher dosages and regular usage result in longer detection times.

 

The type of drug test also affects detection windows. Blood and saliva tests typically detect cannabis metabolites for shorter periods, while urine and hair samples can reveal use for weeks or even months. In some cases, hair tests have detected cannabis use over 90 days after consumption.

 

Detection Windows for Various Cannabis Drug Tests

 

Urine Tests

Among all drug tests, urine testing is the most commonly used method for screening for drug use in an individual.

 

Detection times vary, but a 2017 review suggests the following windows for cannabis in urine after last use:

 

– Single-use (e.g., one joint): up to 3 days

– Moderate use (around 4 times a week): 5–7 days

– Chronic use (daily): 10–15 days

– Chronic heavy use (multiple times daily): over 30 days

 

Blood Tests

Blood tests generally detect recent cannabis use, typically within 2–12 hours after consumption. However, in cases of heavy use, cannabis has been detected up to 30 days later. Chronic heavy use can extend the detection period in the bloodstream.

 

Saliva Tests

THC can enter saliva through secondhand cannabis smoke, but THC metabolites are only present if you’ve personally smoked or ingested cannabis.

 

Saliva testing has a short detection window and can sometimes identify cannabis use on the same day. A 2020 review found that THC was detectable in the saliva of frequent users for up to 72 hours after use, and it may remain in saliva longer than in blood following recent use.

 

In areas where cannabis is illegal, saliva testing is often used for roadside screenings.

 

Hair Tests

Hair follicle tests can detect cannabis use for up to 90 days. After use, cannabinoids reach the hair follicles through small blood vessels and from sebum and sweat surrounding the hair.

 

Hair grows at approximately 0.5 inches per month, so a 1.5-inch segment of hair close to the scalp can reveal cannabis use over the past three months.

 

Factors Affecting THC and Metabolite Retention

 

The length of time THC and its metabolites stay in your system depends on various factors. Some, like body mass index (BMI) and metabolic rate, relate to individual body processing, not the drug itself.

 

Other factors are specific to cannabis use, including:

 

– Dosage: How much you consume

– Frequency: How often you use cannabis

– Method of consumption: Smoking, dabbing, edibles, or sublingual

– THC potency: Higher potency can extend detection time

 

Higher doses and more frequent use generally extend THC retention. Cannabis consumed orally may remain in the system slightly longer than smoked cannabis, and stronger cannabis strains, higher in THC, may also stay detectable for a longer period.

 

How Quickly Do the Effects of Cannabis Set In?

 

When smoking cannabis, effects appear almost immediately, while ingested cannabis may take 1–3 hours to peak.

 

The psychoactive component THC produces a “high” with common effects such as:

 

– Altered senses, including perception of time

– Mood changes

– Difficulty with thinking and problem-solving

– Impaired memory

 

Other short-term effects can include:

– Anxiety and confusion

– Decreased coordination

– Dry mouth and eyes

– Nausea or lightheadedness

– Trouble focusing

– Increased appetite

– Rapid heart rate

– Restlessness and sleepiness

 

In rare cases, high doses may lead to hallucinations, delusions, or acute psychosis.

 

Regular cannabis use may have additional mental and physical effects. While research is ongoing, cannabis use may increase the risk of:

 

– Cognitive issues like memory loss

– Cardiovascular problems including heart disease and stroke

– Respiratory illnesses such as bronchitis or lung infections

– Mood disorders like depression and anxiety

 

Cannabis use during pregnancy can negatively impact fetal growth and development.

 

Duration of Effects

Short-term effects generally taper off within 1–3 hours, but for chronic users, some long-term effects may last days, weeks, or even months. Certain effects may even be permanent.

 

Bottom Line

The amount of time that cannabis remains in your system following a single use varies greatly depending on individual characteristics such as body fat, metabolism, frequency of use, and mode of intake. Frequent users may maintain traces of THC for weeks, whereas infrequent users may test positive for as little as a few days. Hair tests can disclose usage for up to 90 days, while blood and saliva tests identify more recent use. Urine tests are the most popular and have varying detection durations. The duration that THC and its metabolites are detectable will ultimately depend on a number of factors, including dose, strength, and individual body chemistry.

 

PEE IN A CUP COMING UP, READ ON..

how long does weed stay in your urine

HOW LONG DOES WEED STAY IN YOUR URINE FOR A DRUG TEST?



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media